INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Substitute for form 1449/PTO

10 L000 W	(use as many sneets as necessary)	Examiner name	Rei Tsang Shiao	
J	Sheet 1 of 9	Attorney Docket Number	024944-9013-US00	
PADENIS		U.S. Patent Documents		
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
	2,407,823	Fieser	9/17/1946	
	2,913,477	Hirschmann	11/17/1959	
	3,212,901	Robeson	10/19/1965	
	4,075,333	Josse	2/21/1978	
	4,141,938	Klose	2/27/1979	
	4,299,906	Liu	11/10/1981	
	4,369,172	Schor et al.	1/18/1983	
	4,654,373	Bertelli '	3/31/1987	
	4,684,520	Bertelli	8/4/1987	
	4,686,211	Hara et al.	8/11/1987	
	4,874,883	Uphues et al.	10/17/1989	
	4,952,495	Belly et al.	8/29/1991	
	5,094,848	Lubkin	8/20/1991	
	5,053,222	Takasu et al.	10/1/1991	
	5,091,848	Kojima	2/25/1992	
	5,094,848	Brixner	3/10/1992	
	5,114,957	Hendler et al.	5/19/1992	
	5,094,042	Casagrande et al.	8/11/1992	
	5,173,304	Lohner et al.	12/22/1992	
	5,374,645	Kurihara-Bergstrom et al.	12/20/1994	
	5,387,579	Meybeck et al.	2/7/1995	
	5,446,070	Mantelle	8/29/1995	

Examiner Signature		Date Considered	
EXAMINER: Initial if	reference considered, whether or not cita	on is in conformance with MPEP 609. Draw line through citati	on if

not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Bo. Alexandria, VA 22313-1450.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

(use as many sheets as necessary)

Co	mplete if Known
Application Number	10/551,200
Filing Date	August 31, 2006
First named Inventor	Micheal West
Group Art Unit	1626
Examiner name	Rei Tsang Shiao

Sheet 2of 9		Attorney Docket Number	024944-9013-US00				
	U.S. Patent Documents						
Examiner Initials U.S. Patent Document Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document				
	5,474,891	Murphy	12/12/1995				
	5,474,991	Ogata et al.	12/12/1995				
	5,554,781	Reierson	9/10/1996				
	5,570,504	Distefano et al.	11/5/1996				
	5,583,105	Kovacs et al.	12/10/1996				
	5,589,504	Dannenberg et al.	12/31/1996				
	5,603,949	Meybeck et al.	2/18/1997				
	5,607,921	Bernard et al.	3/4/1997				
	5,643,597	Meybeck et al.	7/1/1997				
	5,741,518	Ribier et al.	4/21/1998				
	5,759,526	Simonnet et al.	6/2/1998				
	5,776,915	Peterson et al.	7/7/1998				
	5,780,504	Ptchelintsev	7/14/1998				
	5,804,168	Murad	9/8/1998				
	5,804,216	Terren et al.	9/8/1998				
	5,807,542	Challis et al.	9/15/1998				
	5,807,845	Ogata et al.	9/15/1998				
	5,885,595	Corey et al.	3/23/1999				
	5,906,811	Hersh	5/25/1999				
	5,908,846	Bundgaard et al.	6/1/1999				
	5,916,915	Hong Jong Eon et al.	6/29/1999				
	5,928,631	Lucas et al.	7/27/1999				

Examiner Signature		Date Considered	
DWALED V	10 0		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450.

Substitute for form 1449/PTO Complete if Known Application Number 10/551,200 INFORMATION DISCLOSURE August 31, 2006 Filing Date STATEMENT BY APPLICANT Micheal West First named Inventor Group Art Unit 1626 Examiner name Rei Tsang Shiao (use as many sheets as necessary) 024944-9013-US00

Attorney Docket Number Sheet 3of 9 U.S. Patent Documents U.S. Patent Document Number Name of Patentee or Applicant of Cited Date of Publication of Cited Examiner Initials Document Document 5.965.750 Oonishi et al. 10/12/1999 5,981,474 Manning et al. 11/9/1999 6.022.867 Ito et al. 2/8/2000 6.046.181 Oonishi et al. 4/4/2000 6,048,891 Wechter 4/11/2000 6.096.326 Wikholm 8/1/2000 6.121.249 Weissman et al. 9/19/2000 6,184,247 Schneider 2/6/2001 6,384,043 Peyman et al. 5/7/2002 6.403.811 West 6/11/2002 Sanders et al 6,417,223 7/9/2002 6 423 742 Larson 7/23/2002 6,444,220 Wiley 9/3/2002 6,444,234 Kirby et al. 9/3/2002 6,479,540 Constantinides et al. 11/12/2002 6.579.995 West 6/17/2003 6,599,933 Takada et al 7/29/2003 6 645 998 Sanders et al 11/11/2003 6,703,384 Sanders et al. 3/9/2004 6,770,672 Sanders et al 8/3/2004 7,179,486 Mulye 2/20/2007 2002/0131994 Schur et al. 9/19/2002

Examiner	D.u.	
Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450.

4/28/2005

10/26/2006

11/16/2006

12/14/2006

12/14/2006

2/22/2007

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY ADDITIONAL Filing Date
Application Number | 10/551,200 | Filing Date | August 31, 2006

U.S. Patent Documents U.S. Patent Document Number Name of Patentee or Applicant of Cited Examiner Initials Date of Publication of Cited Document Document 2002/0151467 Leung 10/17/2002 2003/0035812 Ito et al. 2/20/2003 2003/0157326 Vaghefi et al. 8/21/2003 2003/0206972 Babish et al. 11/6/2003 2004/0052754 West et al 3/18/2004 2004/0067890 Gunta 4/8/2004 2004/0096493 West 5/20/2004 2004/0097431 Sanders et al 5/20/2004 2004/0097472 West et al. 5/20/2004 2004/0204343 Fishman 10/14/2004 2004/0234602 Fischer et al. 11/25/2004 2004/0235938 Sanders et al. 11/25/2004 2004/0241225 West 12/2/2004 2004/0253318 West et al 12/16/2004 2005/0009787 West et al. 1/13/2005

Examiner Signature	Date Considered	*

West

West et al.

West et al.

West

West et al

West et al.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

2005/0089495

2006/0241085

2006/0257459

2006/0281715

2006/0281716

2007/0042999

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

(use as many sheets as necessary) Sheet 5of 9

Con	plete if Known	
Application Number	10/551,200	
Filing Date	August 31, 2006	
First named Inventor	Micheal West	
Group Art Unit	1626	
Examiner name	Rei Tsang Shiao	
Attorney Docket Number	024944-9013-11500	

#### U.S. Patent Documents FORFICN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	CA	1337992	Shiseido Co. Ltd. et al.	1/23/1996		х
	EP	0171009	Henkel Corporation	2/12/1986		х
	EP	0324387	Takeda Chemical Industries Ltd.	7/19/1989		х
	EP	0338429	BASF AG	10/25/1989		-
	EP	0430045	Senju Pharmaceutical Co., Inc.	6/5/1991		х
	EP	0430336	Zambon Group SpA	6/5/1991		х
	EP	0436911	Eisai Co., Ltd.	7/17/1991		х
	EP	0565007	Senju Pharmaceutical Co., Inc.	10/13/1993		x
	EP	0574255	Indena SpA	12/15/1993		х
	EP	0617963	Senju Pharmaceutical Co., Inc.	10/5/1994		х
	EP	0641790	Scotia Holdings Plc	3/8/1995		х
	EP	0661053	Senju Pharmaceutical Co., Inc.	7/5/1995		х
	EP	0679399	Senju Pharmaceutical Co., Inc.	11/2/1995		х
- 1	EP	0680760	Senju Pharmaceutical Co., Inc.	11/8/1995		х
	EP	0684043	Senju Pharmaceutical Co., Inc.	12/29/1995		х
	EP	0699440	Senju Pharmaceutical Co., Inc.	3/6/1996		х
	EP	0826365	Senju Pharmaceutical Co., Inc.	3/4/1998		х
	EP	0845216	Showa Denko Kabushiki Kaisha	6/3/1998		х
	EP	0965328	Kao Corporation	12/22/1999		х
	EP	1023897	Showa Denko KK	8/2/2000		х
	EP	1053749	Senju Pharmaceutical Co., Inc.	11/22/2000		х
	GB	1121683	General Aniline & Film	7/31/1968		x

		1121003	Corporation	//31/1908	, X
Examiner Signature				Date Considered	
DW ALED IN	T	1:0 0			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450

English

Abstract

Translation

Date of Publication of Cited

Document

8/8/1990

2/12/1070

Substitute for form 1449/PTO	Complete	if Known
INFORMATION DISCLOSURE	Application Number	10/551,200
	Filing Date	August 31, 2006
STATEMENT BY APPLICANT	First named Inventor	Micheal West
	Group Art Unit	1626
(use as many sheets as necessary)	Examiner name	Rei Tsang Shiao
Sheet 6of 9	Attorney Docket Number	024944-9013-US00

# U.S. Patent Documents FOREIGN PATENT DOCUMENTS Name of Patentee or Da

Applicant of Cited Document

E.R. Squibb & Sons Inc.

Disci Co TAI

Country

Code

GB

Examiner

Initials

Foreign Patent Document

Number

2227662

- 1	JP	53015381	Eisai Co. Ltd.	2/13/1978	X
	JР	58180410	Shiseido Co. Ltd. et al.	10/21/1983	X
	JР	59044375	Senju Seiyaku KK	3/12/1984	х
	JP	59157091	Sanyo Chem. Ind. Ltd.	9/6/1984	х
	JР	61086940	Kao Corporation	5/2/1986	х
	JP	61091137	Kao Corporation	5/9/1986	Х
	JP	61233631	Kao Corporation	10/17/1986	х
	JР	62195393	Yakult Honsha KK	8/28/1987	х
	JР	63139972	Senju Pharmaceutical Co., Inc.	6/11/1988	X
	JР	4208209	Showa Denko KK	7/29/1992	х
	JР	5132700	Sunstar Chemical Industries	5/28/1993	X
	JP	5201858	SS Pharmaceutical Co.	8/10/1993	X
	JP	6048962	Morimoto Kazutoshi	2/22/1994	. X
	JP	6078214	Senju Pharmaceutical Co., Inc.	10/5/1994	Х
	JР	7011291	Kao Corporation	1/13/1995	х
	JР	7278587	Kao Corporation	10/24/1995	х
	JР	7316170	Kao Corporation	12/5/1995	х
	JP	8073338	Noevir KK	3/19/1996	X
	JP	8193089	Kao Corporation	7/30/1996	X
	JP	8311085	Kao Corporation	11/26/1996	Х
	JP	9044375	Hitachi Ltd.	2/14/1997	Х
	JP	9309813	Nonogawa Shoji KK	12/2/1997	х
kaminer gnature			whether or not citation is in conform	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0371.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Substitute for form 1449/PTO	Cor	nplete if Known
INFORMATION DISCLOSURE	Application Number	10/551,200
STATEMENT BY APPLICANT	Filing Date	August 31, 2006
STATEMENT BY APPLICANT	First named Inventor	Micheal West
	Group Art Unit	1626
(use as many sheets as necessary)	Examiner name	Rei Tsang Shiao
Short 7of 9	Attorney Docket Number	024944-9013-US00

#### U.S. Patent Documents

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	JР	10045783	Showa Denko KK	2/17/1998		х
	JP	11043436	Showa Denko KK	2/16/1999		х
	JР	11199424	Nonogawa Shoji KK	7/27/1999		х
	JP	11199465	Nonogawa Shoji KK	7/27/1999	х	X
	ЛР	2001247585	Nippon Oils & Fats Co. Ltd.	9/11/2001		х
	JP	2002080475	Takada Jiro	3/19/2002		х
	SU	925961	MO I T Pishchevoj Promy	5/7/1982		х
	wo	91/17987	SmithKline & French Laboratories Ltd.	11/28/1991		х
	wo	92/03122	CEVC	3/5/1992		х
	wo	92/07544	Senju Pharmaceutical Co., Inc.	5/14/1992		х
	wo	92/08459	Kabi Pharmacia AB	5/29/1992		х
	wo	93/02661	LVMH Rech	2/18/1993 .		х
	wo	93/15731	Lamb	8/19/1993		х
	wo	93/24131	Procter & Gamble Pharmaceuticals Inc.	12/9/1993		х
	wo	95/31217	A/S Dumex	11/23/1995		х
	wo	95/34303	Arcturus Pharmaceutical Corp.	12/21/1995		х
	wo	96/17852	Kao Corporation	6/13/1996		х
	wo	96/20715	Perstorp AB	7/11/1996		х
	wo	96/21440	Alpha-Therapeutics Inc. et al.	7/18/1996		х
	wo	96/29336	Medical Research Council et al.	9/26/1996		х
	wo	97/14705	Showa Denko KK	4/24/1997		х
	wo	97/35591	Inspire Pharmaceuticals Inc.	10/2/1997		х

Examiner	Date
Signature	Considered
EXAMINER: Initi	al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the

individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Bo. Alexandria, VA 22313-1450.

Substitute for form 1449/PTO	Comple	ete if Known
INFORMATION DISCLOSURE	Application Number	10/551,200
STATEMENT BY APPLICANT	Filing Date	August 31, 2006
STATEMENT BY APPLICANT	First named Inventor	Micheal West
	Group Art Unit	1626
(use as many sheets as necessary)	Examiner name	Rei Tsang Shiao
Sheet 8of 9	Attorney Docket Number	024944-9013-US00

### U.S. Patent Documents

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	wo	00/16772	Research Development Foundation	3/30/2000		х
	wo	00/30620	Gasco	6/2/2000		х
	wo	00/43380	Swig Pty. Ltd.	7/27/2000		х
	wo	00/57876	Lipogenics, Inc.	10/5/2000		х
	wo	00/59475	Lipocine Inc.	10/12/2000		х
	wo	00/69865	Swig Pty. Ltd.	11/23/2000		Х
	wo	00/71094	Amway Corporation	11/30/2000		х
	wo	00/71125	LTS Lohmann Therapie- Systeme AG	11/30/2000		х
	wo	01/19372	Pharmacia & Up John SpA	3/22/2001		Х
	wo	01/22937	Sonus Pharmaceuticals, Inc.	4/5/2001		Х
	wo	01/35998	Pharmaderm Laboratories, Ltd.	5/25/2001		х
	wo	01/46204	Merck Frosst Canada & Co.	6/28/2001		х
	wo	01/58889	Research Development Foundation	8/16/2001		х
	wo	02/26238	Tocovite Pty Ltd.	4/4/2002		х
	wo	02/36736	The Regents of University of California	5/10/2002		х
	wo	02/39996	Pharmacia & Up John Company	5/23/2002		х
	wo	02/40033	Tocovite Pty Ltd.	5/23/2002		Х
	wo	02/40034	Tocovite Pty Ltd.	5/23/2002		х
	wo	03/011303	Vital Health Sciences Pty. Ltd.	2/13/2003		х
	wo	03/013550	Vital Health Sciences Pty. Ltd.	2/20/2003		х
	wo	03/024429	Egalet AS	3/27/2003		х

Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Substitute for form 1449/PTO Complete if Known
INFORMATION DISCLOSURE Application Number 10/551,200

U.S. Patent Documents

			FOREIGN PATENT DOCUME	NTS		
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	wo	03/024430	Egalet AS	3/27/2003		х
	wo	03/026673	Vital Health Sciences Pty. Ltd.	4/3/2003		х
	wo	03/039461	Research Development Foundation	5/15/2003		х
	wo	03/043570	Galieo Laboratories Inc.	5/30/2003		х
	wo	03/049774	Vital Health Sciences Pty. Ltd.	6/19/2003		х
	wo	03/053407	Research Development Foundation	7/3/2003		х
	wo	03/101480	Perricone	12/11/2003		х
	wo	2004/014432	Vital Health Sciences Pty. Ltd.	2/19/2004		х
	wo	2004/060315	Perricone	7/22/2004		х
_	wo	2004/064831	Vital Health Sciences Pty. Ltd.	8/5/2004		х
-	wo	2004/091636	Vital Health Sciences Pty. Ltd.	10/28/2004		х
	wo	2004/092186	Vital Health Sciences Pty. Ltd.	10/28/2004		х
	wo	2005/023282	LTT Bio-Pharma Co. Ltd.	3/17/2005		х
	wo	2005/084678	Vital Health Sciences Pty. Ltd.	9/15/2005		х
	wo	2006/012692	Vital Health Sciences Pty. Ltd.	2/9/2006		х
	wo	2006/092024	Vital Health Sciences Pty. Ltd.	9/8/2006		х
	wo	2006/092025	Vital Health Sciences Pty. Ltd.	9/8/2006		х
	wo	2006/133506	Vital Health Sciences Pty. Ltd.	12/21/2006		х
	wo	2007/070981	Vital Health Sciences Pty. Ltd.	6/28/2007		х

Examiner			Date	,
Signature			Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it of

Substitute for form 1449B/PTO					Complete if Known	
Substitute for i	orm 1449B/P1O			Application Number	10/551.200	
INFOR	MATION	DISCL	OSURE	Filing Date	August 31, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Micheal West	
				Group Art Unit	1626	
(use as many sheets as necessary)				Examiner Name	Rei Tsang Shiao	181
Sheet	1	of	6	Attomey Docket Number	024944-9013-US00	

OTHER PRIOR ART. NON PATENT I ITERATIBE DOCUMENTS

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	ABERG, F. et al., "Distribution and redox state of ubiquinones in rat and human tissues," Arch. Biochem. Biophys. (1992) 295(2):230-234
	ALMEIDA, M.E.M. et al., "Evaluation of soybean oil deodorization distillate for Vitamin E recovery," Arq. Biol. Tecnol. (1994) 37(4):1003-1011
	BARRETT, C.W. et al., "The effect of particle size and vehicle on the percutaneous absorption of fluocinolone acetonide," Brit. J. Dermatol. (1965) 77:576-578
	BIKERMAN, J.J., "Mechanical destruction of young and old foam films," J. Phys. Chem. (1952) 56:164-165
Ar.	BLOM, J.H. et al., "Reproductive success of female rainbow trout (Oncorhynchus mykiss) in response to graded dietary ascorbyl monophosphate levels," Biol. of Reproduction (1995) 52:1073-1080
	CEVC, G. "Transdermal drug delivery of insulin with ultradeformable carriers," Clin. Pharmacokinet. (2003) 42(5):461-474
	CEVC, G. et al., "Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin," Biochim. Biophys. Acta (1998) 1368:201-215
	DE WOLFE, F.A. et al., "Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands," Pharmacol. Rev. (2000) 52(2):207-236
	DEVARAJ, S. et al., "Modulation of monocyte-macrophage function with alpha-tocopherol: implications for atherosclerosis," Nat. Rev. (2002) 60(1):8-14

Examiner	Date	4.0
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known			
				Application Number	10/551,200	
INFOR	MATION	N DISCL	OSURE	Filing Date	August 31, 2006	
STATE	EMENT E	BY APPL	ICANT	First Named Inventor	Micheal West	
				Group Art Unit	1626	
	(use as many she	ets as necessary	)	Examiner Name	Rei Tsang Shiao	
Sheet	2	of	6	Attorney Docket Number	024944-9013-US00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	DEVARAJ, S. et al., "Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients," Free Radic. Biol. Med. (2000) 29(8):790-792
	ERNSTER, L. et al., "Biochemical, physiological and medical aspects of ubiquinone function," Biochim. Biophys. Acta (1995) 1271:195-204
	OCTOPLUS, "Formulation Development of Poorly Soluble Drugs" (www.octoplus.nl) (1999) 2 pages (downloaded 11/2008)
	FRACALOSSI, D.M. et al., "Oscars, Astronotus ocellatus, have a dietary requirement for vitamin C," J. Nutrition (1998) 128:1745-1751
	FREI, B. et al., "Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations," Proc. Natl. Acad. Sci. (1990) 87:4879-4883
	GODIN, B. et al., "Ethosomes: new prospects in transdermal delivery," Crit. Rev. Thera. Drug Car. Syst. (2003) 20(1):63-102
	GOFF et al., "Prevention of cardiovascular disease in persons with Type 2 diabetes mellitus: current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) trial," Am. J. Cardiol. (2007) 99(suppl):4i-20i
	GRIFFIN, E. et al., "A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation," Nature Med. (2001) 7(7):840-846
	GUO, J. et al., "Transdermal delivery of insulin in mice by using Lecithin vesicles as a carrier," Drug Del. (2000) 7:113-116

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for f	orm 1449B/PTO				Complete if Known	
Substitute for i	UIII 1447B/1 10			Application Number	10/551,200	
INFORMATION DISCLOSURE				Filing Date	August 31, 2006	
STATEMENT BY APPLICANT			ICANT	First Named Inventor	Micheal West	
(use as many sheets as necessary)				Group Art Unit	1626	
				Examiner Name	Rei Tsang Shiao	
Sheet	3	of	6	Attorney Docket Number	024944-9013-US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	HERON-MILHAVET, L. et al., "Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice," Endocrinology (2004) 145:4667-4676
7	KAGAN, V. et al., "Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling," Biochem. Biophys. Res. Commun. (1990) 169(3):851-857
	KARRER, V.P. et al., "d,l-alpha-tocopherol-phosphorsaure-ester," Zurich, Chemisches Institut der Universitat (1933) p. 1137-1138, in German
	KING, M.J. et al., "Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats," Diab. Tech. Therap. (2002) 4(4):479-488
	KNOWLER, W.C. et al., "Preventing Non-insulin-dependent diabetes," Diabetes (1995) 44:483-488
	LANGSJOEN, P.H. et al., "Overview of the use of CoQ10 in cardiovascular diseases," Biofactors (1999) 9:273-284
	LASS, A. et al., "Electron transport-linked ubiquinone-dependent recycling of α-tocopherol inhibits autooxidation of mitochondrial membranes," Arch. Biochem. Biophys. (1998) 352(2):229-236
	LEE, C-F. et al., "Attenuation of UV-induced apoptosis by coenzyme Q10 in human cells harboring large-scale deltion of mitochontrial DNA," Ann. N.Y. Acad. Sci. (2005) 1042:429-438
	LEI, B. et al.,. "Progress in alpha-tocopherol preparation technology, Xiandai Huagong (1997) 17(7):13-15

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMP number.

	Onder the 1 up		,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	persons are required to respond t	to a concentration of information unless it contains a valid OMB number.
Substitute for f	orm 1449B/PTO				Complete if Known
				Application Number	10/551,200
INFOR	MATION	N DISCL	OSURE	Filing Date .	August 31, 2006
STATE	EMENT B	Y APPL	ICANT	First Named Inventor	Micheal West
				Group Art Unit	1626
	(use as many she	ets as necessary	)	Examiner Name	Rei Tsang Shiao
Sheet	4	of	6	Attomey Docket Number	024944-9013-US00

<u> </u>	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	MAGUIRE, J.J. et al., "Succinate-ubiquinone reductase linked recycling of alpha-tocopherol in reconstituted systems and mitochondria: requirement for reduced ubiquinone," Arch. Biochem. Biophys. (1992) 292(1):47-53
	MELLORS, A. et al., "The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol," J. Biol. Chem. (1966) 241(19):4353-4356
	MERCK INDEX, THE, "α-estradiol" Thirteenth Edition, Whitehouse Station, NJ (2001) page 660
	MERCK INDEX, THE, "Fludarabine to Fludeoxyglucose F18" pages, Thirteenth Edition, Whitehouse Station, NJ (2001) pages 729-730
	MIYAMOTO, S. et al., "Synthesis of a novel phosphate ester of a vitamin E derivative and its antioxidative activity," Biosci. Biotech. Biochem. (1998) 62(12):2463-2466
	MORGAN, T.M. et al., "Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol," J. Pharm. Sci. (1998) 87(10):1226-1228
	MORGAN, T.M. et al., "Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol," J. Pharm. Sci. (1998) 87(10):1219-1225
	MORTENSEN, S.A., "Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone)," Clin. Investig. (1993) 71(Suppl.8):S116-S123
	MUNTEANU, A. et al., "Modulation of cell proliferation and gene expression by alpha-tocopheryl phosphates: relevance to atherosclerosis and inflammation," Biochem. Biophys. Res. Comm. (2004) 318(1):311-316

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, and Additionally a sent of the patent of the p

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for f	orm 1449B/PTO				Complete if Known	
				Application Number	10/551,200	
INFOR	MATION	N DISCL	OSURE	Filing Date	August 31, 2006	
STATE	MENT E	BY APPL	ICANT	First Named Inventor	Micheal West	
				Group Art Unit	1626	
	(use as many she	ets as necessary)	)	Examiner Name	Rei Tsang Shiao	
Sheet	5	of	6	Attorney Docket Number	024944-9013-US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the stricle (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	OSTRENGA, J. et al., "Significance of vehicle composition I: Relationship between topical vehicle composition, skin penetrability, and clinical efficacy," J. Pharm. Sci. (1971) 60(8):1175-1179
	OWENS, D.R. et al., "Alternative routes of insulin delivery," Diabet. Med. (2003) 20:886-898
	PARKER et al., "Neonatal vitamin K administration and childhood cancer in the North of England: retrospective case-control study," BMJ (1998) 316:189-193
	POTTS, R.O. et al., "Predicting skin permeability," Pharm. Res. (1992) 9(5):663-669
	PURATCHIKODY, A. et al., "Reverse phase - high performance liquid chromatographic determination of atorvastatin calcium in solid dosage forms," Pharma. Review (2003) 1(2):79-80, 83 - STN File CA, Abstract 139:399976 only
	SEVASTIANOV, V.I. et al., "Transdermal delivery of insulin," Meditsinskaia Tekhnika (2003) 2:21-24
	SEYAMA, Y. et al., "Comparative effects of Vitamin K2 and estradiol on experiemental arteriosclerosis with diabetes mellitus," Int. J. Vitam. Nutr. Res. (2000) 70(6):301-304, Abstract only
	SINGH, R.B. et al., "Randomized double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction," Cardiov. Drugs Ther. (1998) 12:347-353
	Stedman's Medical Dictionary, "Tocopherol," "Tocotrienol," and "Vitamin K1", 22nd Edition, Williams & Wilkins Co. (1972) p. 1303 and 1400

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, Platent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, 4450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for f	orm 1449B/PTO				Complete if Known
				Application Number	10/551,200
INFOR	MATION	N DISCL	OSURE	Filing Date	August 31, 2006
STATEMENT BY APPLICANT				First Named Inventor	Micheal West
				Group Art Unit	1626
(use as many sheets as necessary)				Examiner Name	Rei Tsang Shiao
Sheet	6	of	6	Attorney Docket Number	024944-9013-US00

	 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	YOUNIS et al., "The prevention of type 2 diabetes mellitus: recent advances," Q.J. Med. (2004) 97:451-455

Examiner	Date	
Signature	Considered	\

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.